GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovacor Inc (AMEX:RCOR) » Definitions » FCF Yield %

Renovacor (Renovacor) FCF Yield % : -55.95 (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Renovacor FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Renovacor's Trailing 12-Month Free Cash Flow is $0.00 Mil, and Market Cap is $55.26 Mil. Therefore, Renovacor's FCF Yield % for today is -55.95%.

The historical rank and industry rank for Renovacor's FCF Yield % or its related term are showing as below:

RCOR' s FCF Yield % Range Over the Past 10 Years
Min: -55.95   Med: 0   Max: 0
Current: -55.95


RCOR's FCF Yield % is not ranked
in the Biotechnology industry.
Industry Median: -14.22 vs RCOR: -55.95

Renovacor's FCF Margin % for the quarter that ended in Sep. 2022 was 0.00%.


Renovacor FCF Yield % Historical Data

The historical data trend for Renovacor's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovacor FCF Yield % Chart

Renovacor Annual Data
Trend Dec20 Dec21
FCF Yield %
- -12.08

Renovacor Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
FCF Yield % Get a 7-Day Free Trial Premium Member Only -13.45 -19.41 -48.72 -95.24 -78.38

Competitive Comparison of Renovacor's FCF Yield %

For the Biotechnology subindustry, Renovacor's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovacor's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovacor's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Renovacor's FCF Yield % falls into.



Renovacor FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Renovacor's FCF Yield % for the fiscal year that ended in Dec. 2021 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-15.58 / 129.0212
=-12.08%

Renovacor's annualized FCF Yield % for the quarter that ended in Sep. 2022 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-8.281 * 4 / 42.258888
=-78.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renovacor FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Renovacor FCF Yield % Related Terms

Thank you for viewing the detailed overview of Renovacor's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovacor (Renovacor) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 8142, Greenwich, CT, USA, 06836
Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.
Executives
Joseph S Carroll officer: Chief Accounting Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Gregory F Covino director C/O RICHARD W DAVIES HUBBELL INC, 684 DERBY MILFORD RD, ORANGE CT 06477
Joan Lau director C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Needham Thomas E. Jr. director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Frederick W Driscoll officer: Chief Financial Officer
Jonas Grossman director 17 STREET, SUITE 1600, NEW YORK NY 10004
Gbolahan Amusa director 17 STATE STREET 21 FLOOR, NEW YORK NY 10004
Magdalene Cook director, officer: Chief Executive Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Matthew Killeen officer: Chief Scientific Officer C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Master Fund, Ltd. 10 percent owner C/O WALKERS CORPORATE LIMITED, 190 ELGIN AVENUE, GEORGE TOWN, GRAND CAYMAN E9 KY1-9008
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Marc Semigran officer: Chief Medical Officer C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Wendy F Dicicco officer: Interim CFO

Renovacor (Renovacor) Headlines